CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma. The multi-center study with MLN8237, an investigational, oral, selective inhibitor of Aurora A kinase, will be conducted in Europe, North America, Latin America and the Asia-Pacific region.
